Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ginkgo biloba, commonly called the maidenhair tree, is a unique, ancient gymnosperm species with no close living relatives, often referred to as a “living fossil.” Extracts of Ginkgo biloba leaves contain a variety of bioactive terpenoids and flavonoids, notably ginkgolides and bilobalide, which have been studied for cognitive, neuroprotective, and vascular effects. Despite widespread use as a supplement, Ginkgo biloba itself is not a molecular or receptor drug target; rather, it is a botanical species that provides complex mixtures of compounds affecting various biological pathways, but it has no approved therapeutic indications and only limited, often inconclusive, evidence of clinical efficacy for any disease. Caution is warranted due to known risks of allergy, toxicity, drug interactions, and lack of robust regulatory oversight[3][4][1].
Antioxidant activity (scavenging free radicals); Inhibition of platelet-activating factor; Inhibition of monoamine oxidase A; Anticholinesterase activity; Inhibition of lipid peroxidation; Modulation of neurotransmitter uptake (serotonin, dopamine, norepinephrine reuptake inhibition)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ginkgo biloba.